Published in Oncology on January 01, 2003
Desmoplastic small round cell tumor of the abdomen and pelvis: clinicopathological characters of 12 cases. ScientificWorldJournal (2014) 0.91
Primary desmoplastic small round cell tumor of the duodenum. Eur J Med Res (2014) 0.78
Combined resection and multi-agent adjuvant chemotherapy for desmoplastic small round cell tumor arising in the abdominal cavity: report of a case. World J Gastroenterol (2006) 0.78
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol (2007) 2.24
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol (2007) 2.24
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol (2007) 2.08
Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. J Clin Oncol (2002) 1.75
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol (2004) 1.64
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res (2003) 1.61
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol (2012) 1.55
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol (2010) 1.52
Performance at preoperative stair-climbing test is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer. Ann Thorac Surg (2012) 1.49
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Oncology (2011) 1.48
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer (2010) 1.40
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev (2010) 1.24
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 1.23
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer (2006) 1.16
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat (2010) 1.13
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2013) 1.08
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res (2010) 1.07
Some practical considerations for phase III studies with biomarker evaluations. J Clin Oncol (2014) 1.07
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int (2012) 1.07
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin Cancer Res (2014) 1.06
Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol (2008) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res (2008) 1.01
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer (2013) 1.01
Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res Int (2013) 1.00
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther (2010) 1.00
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist (2011) 0.97
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev (2004) 0.97
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. Clin Chem Lab Med (2007) 0.96
Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. Eur J Hum Genet (2006) 0.96
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS One (2013) 0.95
Pain and its treatment in hospitalized patients with metastatic cancer. Support Care Cancer (2003) 0.95
Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets (2010) 0.95
5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics (2011) 0.93
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis (2012) 0.92
Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother (2007) 0.90
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer (2013) 0.89
Essential role of Gli proteins in glioblastoma multiforme. Curr Protein Pept Sci (2013) 0.89
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer (2010) 0.88
Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming? Curr Cancer Drug Targets (2013) 0.87
CAT25 is a mononucleotide marker to identify HNPCC patients. J Mol Diagn (2009) 0.87
Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer. J Thorac Cardiovasc Surg (2013) 0.87
The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone. Cancer Invest (2003) 0.86
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev (2009) 0.86
Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. Med Oncol (2004) 0.85
MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system. Hum Mutat (2008) 0.85
Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep (2003) 0.85
Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. J Clin Oncol (2005) 0.85
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol (2007) 0.85
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol (2013) 0.85
Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer. Eur J Cardiothorac Surg (2012) 0.85
Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer (2003) 0.84
Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy. Dis Colon Rectum (2007) 0.84
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. Tumour Biol (2004) 0.82
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clin Sarcoma Res (2013) 0.82
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori (2012) 0.81
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori (2006) 0.81
Compliance with breast and cervical cancer screening programs in women: results from a population-based study. Tumori (2013) 0.81
Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. Recent Pat Antiinfect Drug Discov (2012) 0.80
Effective prevention of 5-fluorouracil-induced superficial phlebitis by ketoprofen lysine salt gel. Am J Med (2003) 0.80
Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer (2006) 0.80
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. J Neurooncol (2013) 0.80
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? Lung Cancer (2009) 0.80
BRCA1 expression in triple negative sporadic breast cancers. Anal Quant Cytol Histol (2010) 0.79
Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori (2012) 0.79
The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. Dig Liver Dis (2010) 0.79
A cost-benefit analysis of chemotherapy for gastric cancer. Expert Opin Pharmacother (2004) 0.78
Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy. Curr Oncol Rep (2010) 0.78
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adh Migr (2015) 0.78
Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. Anal Quant Cytol Histol (2009) 0.78
The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy. Crit Rev Oncol Hematol (2010) 0.78
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drugs (2010) 0.78
Emerging Immunotargets and Immunotherapies in Prostate Cancer. Curr Drug Targets (2016) 0.78
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study. J Immunother (2010) 0.77
Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. Expert Opin Ther Targets (2006) 0.77
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat (2007) 0.77
Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. Anticancer Res (2013) 0.77
A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-Italy. Fam Cancer (2007) 0.77
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemother Pharmacol (2010) 0.77
Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib. J Thorac Oncol (2009) 0.77
Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination. Oncology (2005) 0.76
State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Discov Med (2011) 0.76
Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol (2002) 0.76
Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer. Anal Quant Cytol Histol (2006) 0.75
S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res (2004) 0.75
Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. Tumori (2011) 0.75
[Non-small cell lung carcinoma: pathology, biology and prognosis]. Suppl Tumori (2004) 0.75
Adenocarcinoma arising from ileoanal J-pouch mucosa: an announced event? Inflamm Bowel Dis (2011) 0.75
[The DUR studies: colon cancer adjuvants]. Suppl Tumori (2004) 0.75